Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC. We’re routinely using next-generation sequencing [NGS] in ...
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic ...
New Working Group to Evaluate Clinical Utility of NGS-Based Testing to Inform Coverage After many years of steady development in DNA sequencing, the scientific community is reaching an exciting ...
The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board. This is ...
While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
NORTHFIELD, Ill.--(BUSINESS WIRE)--Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving ...
“It’s important for patients to be educated on (next-generation sequencing), because the more we know about a patient’s cancer, the better we can design a personalized treatment plan,” says an expert.
Recommendations on the use of next-generation sequencing (NGS) tests for patients with metastatic cancer have been issued by the European Society for Medical Oncology (ESMO), the first recommendations ...
Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...
Fulgent Genetics will partner with MedScan Laboratory to launch one of the market’s first COVID-19 tests based on comprehensive Next Generation Sequencing technology TEMPLE CITY, Calif., March 17, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results